BTC$62,618.00-0.25%
ETH$1,784.25+0.38%
USDT$0.9988-0.04%
BNB$569.17+0.14%
USDC$0.9999+0.01%
XRP$1.07-0.61%
SOL$75.19-1.62%
TRX$0.3249-1.59%
FIGR_HELOC$1.03+1.91%
HYPE$63.74-2.41%
DOGE$0.0723+0.10%
USDS$0.99970.00%
RAIN$0.0143-0.35%
LEO$9.54+0.05%
ZEC$507.59-1.85%
WBT$54.95-0.04%
BTC$62,618.00-0.25%
ETH$1,784.25+0.38%
USDT$0.9988-0.04%
BNB$569.17+0.14%
USDC$0.9999+0.01%
XRP$1.07-0.61%
SOL$75.19-1.62%
TRX$0.3249-1.59%
FIGR_HELOC$1.03+1.91%
HYPE$63.74-2.41%
DOGE$0.0723+0.10%
USDS$0.99970.00%
RAIN$0.0143-0.35%
LEO$9.54+0.05%
ZEC$507.59-1.85%
WBT$54.95-0.04%
Eli Lilly shares surged over 4.5% on analyst upgrades, acquisition rumors involving Ventyx Biosciences, and a new $1.3 billion research partnership.
The assassination of UnitedHealthcare CEO Brian Thompson has sparked a national debate on healthcare reform in the United States.
Eli Lilly and Novo Nordisk continue to capitalize on unprecedented interest for weight-loss drugs, with both companies posting strong Q3 results on Thursday.
Several drugmakers have been thriving on the ongoing weight-loss trend, with Denmark's Novo Nordisk and Eli Lilly standing out in particular.
Shares of drugmaker Ars Pharmaceuticals crashed over 57% after FDA disapproved its EpiPen alternative.
Got an extra $500? Take a look at these long-term, much-anticipated stocks.